Calithera Biosciences, Inc.
CALAOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$1462
P/E Ratio—
52W High$0.002
52W Low$0.0001
Calithera Biosciences, Inc. (CALA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CALA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.01B | $0.00B | $0.00B | $0.02B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.01B | ($0.00B) | ($0.00B) | $0.02B |
| Gross Margin %(computed) | — | 85.29% | — | — | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.03B | $0.10B | $0.07B | $0.08B | $0.07B |
| G&A Expenses | $0.01B | $0.02B | $0.02B | $0.02B | $0.01B |
| Total Operating Expenses | $0.04B | $0.12B | $0.09B | $0.09B | $0.08B |
| Operating Income | ($0.04B) | ($0.11B) | ($0.09B) | ($0.09B) | ($0.06B) |
| Operating Margin %(computed) | — | — | — | — | -257.40% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.04B) | ($0.12B) | ($0.09B) | ($0.09B) | ($0.05B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Net Income | ($0.02B) | ($0.12B) | ($0.09B) | ($0.09B) | ($0.05B) |
| Net Margin %(computed) | — | — | — | — | -231.29% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-7.94 | $-31.16 | $-26.20 | $-36.50 | $-28.12 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.04B) | ($0.11B) | ($0.09B) | ($0.09B) | ($0.06B) |
| EBITDA Margin %(computed) | — | — | — | — | -257.40% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Calithera Biosciences, Inc. data
About Calithera Biosciences, Inc. (CALA) Income Statement
Calithera Biosciences, Inc. (CALA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, CALA reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.02B) — a net profit margin of —.
Frequently asked questions
CALA · 4 questionsCalithera Biosciences, Inc. (CALA) reported revenue of $0.00B for 2022, down 100.0% year-over-year.
CALA revenueCALA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08